PhaseBio Pharmaceuticals

PhaseBio is a clinical-stage biopharmaceutical company dedicated to developing new and improved drugs, initially focusing on endocrine and metabolic diseases and cardiovascular diseases. The company uses its proprietary recombinant biopolymers, known as elastin-like polypeptides (ELPs), to enhance the stability, bioavailability, activity, and ease of management of proteins and peptides, aiming for greater efficacy, fewer side effects, and better patient compliance. Efficient E. coli production ensures low-cost products.